NASDAQ:MYGN - Myriad Genetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.46 +0.55 (+1.78 %)
(As of 02/18/2019 01:59 PM ET)
Previous Close$30.91
Today's Range$30.50 - $31.65
52-Week Range$26.05 - $50.44
Volume1.24 million shs
Average Volume1.02 million shs
Market Capitalization$2.31 billion
P/E Ratio26.22
Dividend YieldN/A
Beta0.71
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$772.60 million
Cash Flow$2.0670 per share
Book Value$14.52 per share

Profitability

Net Income$131.10 million

Miscellaneous

Employees2,400
Market Cap$2.31 billion
OptionableOptionable

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its earnings results on Tuesday, February, 5th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.04. The firm had revenue of $216.80 million for the quarter, compared to analysts' expectations of $217.69 million. Myriad Genetics had a net margin of 3.25% and a return on equity of 9.79%. The business's revenue was up 15.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 EPS. View Myriad Genetics' Earnings History.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY19 earnings guidance on Tuesday, February, 5th. The company provided earnings per share (EPS) guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.76. The company issued revenue guidance of $855-865 million, compared to the consensus revenue estimate of $866.29 million.Myriad Genetics also updated its FY 2019 guidance to $1.70-1.75 EPS.

What price target have analysts set for MYGN?

10 Wall Street analysts have issued 1 year target prices for Myriad Genetics' stock. Their predictions range from $21.00 to $54.00. On average, they anticipate Myriad Genetics' share price to reach $40.8578 in the next year. This suggests a possible upside of 29.9% from the stock's current price. View Analyst Price Targets for Myriad Genetics.

What is the consensus analysts' recommendation for Myriad Genetics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

Headlines about MYGN stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myriad Genetics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.32%), Baillie Gifford & Co. (12.94%), D. E. Shaw & Co. Inc. (5.35%), Frontier Capital Management Co. LLC (4.31%), Dimensional Fund Advisors LP (3.46%) and Acadian Asset Management LLC (2.49%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Millennium Management LLC, Acadian Asset Management LLC, Prudential Financial Inc., Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, Tieton Capital Management LLC and Voloridge Investment Management LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Dennis Langer, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone and Richard M Marsh. View Insider Buying and Selling for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Frontier Capital Management Co. LLC, Geode Capital Management LLC, SG Americas Securities LLC, Bank of New York Mellon Corp, Falcon Point Capital LLC and CWM LLC. View Insider Buying and Selling for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $31.46.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.31 billion and generates $772.60 million in revenue each year. The company earns $131.10 million in net income (profit) each year or $1.20 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is http://www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  382 (Vote Outperform)
Underperform Votes:  608 (Vote Underperform)
Total Votes:  990
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Retained Earnings

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel